Ashwin N. Ananthakrishnan
Expertise in
18
conditions

Dr. Ashwin N. Ananthakrishnan

Gastroenterology
Office
165 Cambridge St Fl 9, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Expertise in
18
conditions
Office
165 Cambridge St Fl 9, 
Boston, MA 

Overview

Ashwin Ananthakrishnan is a Gastroenterologist practicing medicine in Boston, Massachusetts.

Dr. Ananthakrishnan is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ulcerative Colitis, Crohn's Disease, Viral Gastroenteritis, Colonoscopy, and Endoscopy.

He is actively involved in clinical research, co-authoring 452 peer reviewed articles and participating in 9 clinical trials. Dr. Ananthakrishnan is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in WI

Hospital Affiliations

Newton-Wellesley Hospital
Massachusetts General Hospital
North Shore Medical Center -
Brigham And Women's Hospital
Wentworth-Douglass Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunshine Health
  • EPO
  • HMO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Office
165 Cambridge St Fl 9, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome
A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)
Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Other
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Enrollment Status: Terminated
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drug: TAK-018
Study Phase: Phase 2
GI Complications in Cancer Immunotherapy Patients
GI Complications in Cancer Immunotherapy Patients
Enrollment Status: Unknown
Publish Date: April 05, 2022
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

450 Total Publications

Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy.
Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy.
Journal: Journal of Crohn's & colitis
Published: June 30, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Gilaad G. Kaplan
Gastroenterology
Expertise in
18
conditions
Dr. Gilaad G. Kaplan
Gastroenterology
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-726-3673
Languages Spoken:
English

Gilaad Kaplan is a Gastroenterologist practicing medicine in Boston, Massachusetts. Dr. Kaplan is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Colitis, Endoscopy, and Colonoscopy.

Expertise in
16
conditions
Dr. Hamed Khalili
Gastroenterology
Expertise in
16
conditions
Dr. Hamed Khalili
Gastroenterology
Referral may be required

Office

165 Cambridge St Fl 9, 
Boston, MA 
 (0.1 miles away)
617-726-7933
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hamed Khalili is a Gastroenterologist practicing medicine in Boston, Massachusetts. Dr. Khalili is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Ulcerative Colitis, Lymphocytic Colitis, Crohn's Disease, Colonoscopy, and Endoscopy. Dr. Khalili is currently accepting new patients.

Expertise in
27
conditions
Dr. Andrew T. Chan
Gastroenterology
Expertise in
27
conditions
Dr. Andrew T. Chan
Gastroenterology
Referral may be required

Office

243 Charles St Ste 1107, 
Boston, MA 
 (0.1 miles away)
617-273-5699
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Chan is a Gastroenterologist practicing medicine in Boston, Massachusetts. Dr. Chan is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Diverticular Disease, Familial Colorectal Cancer, Colonoscopy, and Endoscopy. Dr. Chan is currently accepting new patients.

Frequently Asked Questions about Dr. Ashwin N. Ananthakrishnan

How do I make an appointment with Dr. Ashwin N. Ananthakrishnan?

You can book an appointment with Dr. Ashwin N. Ananthakrishnan by calling their office at 617-726-3661. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ashwin N. Ananthakrishnan a top-rated expert for Ulcerative Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ashwin N. Ananthakrishnan is classified as an Elite expert for Ulcerative Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ashwin N. Ananthakrishnan specialize in?

While Dr. Ashwin N. Ananthakrishnan is a Gastroenterology, they have specific expertise in Ulcerative Colitis, Crohn's Disease, and Viral Gastroenteritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Ashwin N. Ananthakrishnan participate in research or clinical trials?

Yes. Dr. Ashwin N. Ananthakrishnan has published 450 articles and abstracts on conditions like Ulcerative Colitis. You can view a list of Dr. Ashwin N. Ananthakrishnan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ashwin N. Ananthakrishnan accept my insurance?

Dr. Ashwin N. Ananthakrishnan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-726-3661 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ananthakrishnan's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile